Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMA203CD8 GEN2
- Development stage
- Unknown
- Lead developer
- Immatics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
IMA203CD8 GEN2 is a second-generation, autologous T-cell receptor (TCR) engineered T-cell therapy developed by Immatics. It is designed to target the PRAME (PReferentially expressed Antigen in MElanoma) antigen, a cancer-testis antigen highly expressed in various solid tumors. Unlike the first-generation IMA203, this GEN2 version involves the co-transduction of T cells with both a PRAME-specific TCR and a CD8αβ co-receptor. This modification is intended to functionalize CD4+ T cells, enabling them to contribute directly to the anti-tumor response alongside CD8+ T cells, thereby enhancing the overall potency and durability of the therapy. It is currently being evaluated in Phase 1 clinical trials for advanced solid tumors, including melanoma, ovarian cancer, and uterine cancer, specifically in patients who are HLA-A*02:01 positive.
- Other names
- IMA203CD8IMA-203CD8IMA 203CD8
02
Targets
HLA-A*02:01/PRAME (HLA-A*02:01-restricted Preferentially Expressed Antigen in Melanoma (PRAME) peptide complex)
Beyond the preview
Go deeper on IMA203CD8 GEN2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMA203CD8 GEN2.